



## PROFESSIONAL IDENTITY FORMATION IN MEDICAL EDUCATION FOR HUMANISTIC, RESILIENT PHYSICIANS

How can we effectively nurture the intricate and iterative PIF process for health care professionals who embody humanistic and resilient qualities? Moreover, how can we provide the essential scaffolding for learners to develop a critical reflective learning and practice skill set, shaping a robust professional identity?

Go [here](#) to explore innovative pedagogies shaping the professional identity of humanistic and resilient physicians.

### TABLE OF CONTENTS

Save the Date: GMDP Academy 2023  
Graduation Ceremony • P. 2

---

Addressing Long Covid Inequities  
across a Socioeconomic Spectrum •  
P. 3

---

Partnership Propels Cancer Grand  
Challenges Initiative • P. 3

---

Child-friendly Tuberculosis  
Medicines in Europe • P. 4

---

The HOPE Act's Decade of Progress  
in HIV and Organ Transplantation •  
P. 4

---

Empowering Healthcare: The Rise  
of Artificial Intelligence in Modern  
Medicine • P. 5

# Graduation Ceremony

2023 Cohort



We are thrilled to announce the inaugural Graduation Ceremony of the GMDP Academy, celebrating the remarkable achievements of our students who have successfully completed the Certification in Medicines Development program this academic year.

Save the Date:

Date & Time: 10AM – 11:15AM EST, Tuesday, January 30, 2024

Location: Virtual via Zoom

[Click here to register](#)

This pivotal event signifies not just the conclusion of a demanding academic journey but also the continuance of promising careers in the field of medicines development.

The ceremony agenda will feature:

- An enlightening keynote address
- Recognition of our graduates
- Insights from program participants
- Acknowledgements to our esteemed sponsors
- Thought-provoking closing remarks.

The palpable enthusiasm from our academic staff and the graduates guarantees an event brimming with gratitude, introspection, and hopeful anticipation.

We kindly encourage sharing this invitation with colleagues and anyone invested in the future of medicines development. This ceremony is an opportunity for our entire community to come together in celebration of our collective accomplishments.

Please mark your calendars, register using the provided link, amplify the message on platforms like LinkedIn, and watch out for further updates.

## ADDRESSING LONG COVID INEQUITIES IN COUNTRIES ACROSS A SOCIOECONOMIC SPECTRUM

The COVID-19 pandemic has brought to light significant societal disparities, both within individual societies and among different nations. In the past three years, inequities have become glaringly evident in various aspects, including research capabilities, surveillance infrastructure, and the availability of treatments and vaccines. These discrepancies are particularly stark when comparing high-income countries (HICs) with low- and middle-income countries (LMICs). Moreover, substantial gaps persist among countries in terms of research efforts and coordinated national responses to address the long-term consequences of COVID-19, commonly known as long COVID or post-COVID-19 condition. The World Health Organization (WHO) defines post-COVID-19 condition as a complex-



multi-system ailment characterized by symptoms persisting in individuals for at least three months after recovering from acute SARS-CoV-2 infection, with no alternative diagnosis available. Continue reading [here](#).<sup>1</sup>

## PARTNERSHIP PROPELS CANCER GRAND CHALLENGES INITIATIVE WITH €10 MILLION BOOST




The Cancer Grand Challenges initiative is set to receive a significant funding boost through a strategic partnership between the French Institut National Du Cancer (INCa) in Boulogne-Billancourt, France, and Cancer Research UK based in London. This collaboration aims to enhance financial support for the initiative by providing an additional €10 million (£8.6 million) for the upcoming round of winning bids, scheduled to be announced in March 2024.

Bruno Quesnel, a representative from INCa, emphasized the need for substantial investments to achieve groundbreaking advancements in cancer treatment. Over the past three decades, progress in cancer treatments has been gradual, and Quesnel emphasized the necessity for a more disruptive approach.<sup>2</sup> Read more [here](#).

# FACING THE UNMET NEED: CHILD-FRIENDLY TUBERCULOSIS MEDICINES IN EUROPE

Across European nations, the availability of first-line medicines for treating drug-susceptible tuberculosis (DS-TB) varies significantly, raising concerns, especially in the realm of child-friendly medications. Instances have been reported where physicians were compelled to modify or combine formulations designed for adults to treat pediatric TB cases. This reliance on suboptimal treatment options poses potential challenges such as decreased compliance, uncertain effects on treatment outcomes, and unpredictable toxicity. Moreover, the use of these alternatives may elevate the risk of developing drug-resistant TB.

This study meticulously examined the availability and utilization of TB medicines within the-



European Union (EU) and European Economic Area (EEA), with a specific emphasis on formulations suitable for children. Continue reading [here](#).<sup>3</sup>

# THE HOPE ACT'S DECADE OF PROGRESS IN HIV AND ORGAN TRANSPLANTATION




Over the course of four decades of global research on HIV, significant strides have been made in the treatment of the virus, not only prolonging life but also markedly enhancing the well-being of those affected, contingent upon adequate access to healthcare. This success, however, has introduced fresh challenges, particularly in light of the emergence of life-threatening comorbidities associated with the natural aging process.

For individuals grappling with end-stage organ diseases, organ transplantation emerges as a crucial and potentially life-saving recourse, irrespective of their HIV serological status. A pivotal moment in this regard occurred a decade ago with the introduction of the HIV Organ Policy Equity Act (HOPE Act) in the United States. Read more [here](#).<sup>4</sup>

# EMPOWERING HEALTHCARE: THE RISE OF ARTIFICIAL INTELLIGENCE IN MODERN MEDICINE

The integration of artificial intelligence (AI) into medicine involves utilizing machine learning models to analyze medical data, extracting valuable insights to enhance health outcomes and patient experiences. Recent advancements in computer science and informatics have rapidly established AI as an essential component of contemporary healthcare.<sup>5</sup>



Continue reading [here](#).

## REFERENCES

1. Jassat, W., Reyes, L. F., Munblit, D., Caoili, J., Bozza, F. A., Hashmi, M., Edelstein, M., Cohen, C., Álvarez-Moreno, C., & Cao, B. (2023). Long COVID in low-income and middle-income countries: the hidden public health crisis. *The Lancet*, 402(10408), 1115–1117. [https://doi.org/10.1016/s0140-6736\(23\)01685-9](https://doi.org/10.1016/s0140-6736(23)01685-9)
2. Wilkinson, E. (2023). UK and France form partnership to tackle greatest challenges in cancer. *Lancet Oncology*, 24(11), 1172. [https://doi.org/10.1016/s1470-2045\(23\)00509-0](https://doi.org/10.1016/s1470-2045(23)00509-0)
3. Cherchi, A., Vaz, A., Coelho, A. C., Fregonese, L., & Thirstrup, S. (2023). Tuberculosis medicines for children in Europe: an unmet medical need. *ERJ Open Research*, 9(4), 00730–02022. <https://doi.org/10.1183/23120541.00730-2022>
4. Hiv, L. (2023). Transplant donation without discrimination. *The Lancet HIV*, 10(11), e693. [https://doi.org/10.1016/s2352-3018\(23\)00269-2](https://doi.org/10.1016/s2352-3018(23)00269-2)
5. Wald, H. S., Anthony, D., Hutchinson, T., Liben, S., Smilovitch, M., & Donato, A. A. (2015). Professional Identity formation in medical education for humanistic, resilient physicians. *Academic Medicine*, 90(6), 753–760. <https://doi.org/10.1097/acm.0000000000000725>

## Thanks for reading!

The GMDP Academy Newsletter is published twice monthly and is compiled by the following:

**Medical Editor:** Domenico Criscuolo

**Media Manager:** Whitney English

**Editorial Board:** Pravin Chopra, Jacob Coots, Honorio Silva, Peter Stonier

**Operations Office:** Amanda Schmitt, Gustavo Silva, Kit Vale

## CONTACT US:



420 Lexington Ave. Ste. 300  
New York, NY 10170

(332) 333-2438